Nykode Therapeutics AS (OTCMKTS:VACBF) Sees Large Growth in Short Interest

Nykode Therapeutics AS (OTCMKTS:VACBF) was the target of a large growth in short interest in February. As of February 15th, there was short interest totalling 2,193,400 shares, a growth of 83.1% from the January 31st total of 1,197,800 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days.

Nykode Therapeutics AS Price Performance

VACBF opened at $0.22 on Friday. The company has a 50-day simple moving average of $0.24 and a 200 day simple moving average of $0.42. Nykode Therapeutics AS has a twelve month low of $0.22 and a twelve month high of $0.95.

About Nykode Therapeutics AS

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10.